Hyperalgesia and NMDA Receptor Antagonist

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02087202

Enrollment

Registered

2014-03-14

Start date

2014-03-31

Completion date

2014-07-31

Last updated

2014-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

pain

Brief summary

NMDA receptor is administered and postoperative remote hyperalgesia is investigated.

Detailed description

NMDA receptor is adminstered and postoperative tertiary hyperalgesia is investigated. QST and pain measures for remote hyperalgesia are compared between control and magnesium or ketamine group.

Interventions

DRUGMagnesium Sulfate

magnesium sulfate is added to the patients

DRUGketamine

ketamine is added to the patients.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* ASA1-2

Exclusion criteria

* contraindication to the study drugs

Design outcomes

Primary

Measure	Time frame	Description
pain	until 1 month from the end of the operation	pain (QST and pain measures )until 1 month from the end of the operation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026